CSBR · XBRL financial data

Champions Oncology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CSBR's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Revenue from contracts with customers	11,573	12,019	14,002*	14,061	13,489	17,039	12,355*	13,995	15,035	16,559	13,835*	15,232
Cost of goods and services sold	6,618	7,849	7,250*	7,072	7,428	6,617	7,271*	7,995	7,262	8,834	6,810*	7,534
Research and development	2,515	2,186	2,050*	1,454	1,689	1,719	1,963*	2,082	2,616	2,271	2,115*	2,344
General and administrative	2,600	2,764	2,762*	2,527	1,889	2,398	2,526*	2,570	2,974	2,975	2,633*	2,673
Operating income (loss)	(1,955)	(2,577)	(271)*	1,329	732	4,499	(2,007)*	(527)	185	(276)	(522)*	(409)
Other income (expense)	(105)	58	81*	5	7	19	43*	75	70	39	27*	(6)
Income tax expense (benefit)	11	11	(81)*	21	11	23	(129)*	14	18	42	172*	11
Net income (loss)	(2,071)	(2,530)	(109)*	1,313	728	4,495	(1,835)*	(436)	268	(279)	(667)*	(426)
Earnings per share, basic USD per share	(0.15)	(0.19)	(0.01)*	0.10	0.05	0.33	(0.13)*	(0.03)	0.02	(0.02)	(0.05)*	(0.03)
Earnings per share, diluted USD per share	(0.15)	(0.19)	(0.01)*	0.09	0.05	0.31	(0.13)*	(0.03)	0.02	(0.02)	(0.05)*	—
Weighted average shares, basic thousands of shares	13,497	13,594	13,594*	13,594	13,594	13,701	13,754*	13,788	13,792	13,887	13,863*	13,898
Weighted average shares, diluted thousands of shares	13,497	13,594	13,594*	14,042	14,017	14,365	14,656*	13,788	14,458	13,887	13,175*	—

Balance sheet

CSV

Fiscal quarters (CSBR's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Cash and cash equivalents	5,513	4,468	2,618	2,892	2,754	3,202	9,785	10,325	8,516	7,127	4,872	4,358
Accounts receivable	7,724	7,895	9,526	9,032	10,470	15,782	11,234	9,474	11,539	12,067	13,178	13,602
Prepaid and other current assets	780	835	1,495	1,254	860	713	1,350	1,215	1,277	991	1,169	1,332
Total current assets	14,017	13,198	13,639	13,178	14,084	19,697	22,369	21,014	21,332	20,185	19,219	19,292
Right-of-use asset	6,816	6,536	6,252	5,963	5,669	5,370	5,080	4,771	4,348	4,026	3,697	9,675
Goodwill	335	335	335	335	335	335	335	335	335	335	335	335
Total assets	28,294	26,787	26,132	24,933	25,240	30,627	32,344	30,546	30,162	28,447	26,989	33,290
Accounts payable	4,536	4,756	5,800	5,235	4,854	5,093	4,248	4,845	5,993	5,726	6,903	5,632
Accrued liabilities	2,023	2,430	2,160	2,097	2,235	2,267	2,556	1,801	2,188	3,346	2,592	2,676
Total current liabilities	20,950	21,969	21,541	19,164	18,861	19,870	23,853	22,698	22,141	20,677	19,922	18,729
Lease liability, non-current	6,775	6,437	6,093	5,738	5,374	5,003	4,634	4,244	3,744	3,365	2,992	9,886
Total liabilities	28,201	28,845	28,035	25,265	24,559	25,158	28,572	27,008	25,931	24,069	22,921	28,830
Accumulated deficit	(81,954)	(84,484)	(84,593)	(83,280)	(82,552)	(78,057)	(79,892)	(80,358)	(80,121)	(80,400)	(81,067)	(81,493)
Total stockholders' equity	93	(2,058)	(1,903)	(332)	681	5,469	3,772	3,508	4,170	4,283	3,939	3,893
Total liabilities and equity	28,294	26,787	26,132	24,933	25,240	30,627	32,344	30,546	30,162	28,447	26,989	33,290
Common shares outstanding (cover page) thousands of shares	13,594	13,594	13,594	13,594	13,819	13,827	13,777	13,788	13,886	13,887	13,894	13,919

Cash flows

CSV

Fiscal quarters (CSBR's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Net income (loss)	(2,071)	(2,530)	(109)*	1,313	728	4,495	(1,835)*	(436)	268	(279)	(667)*	(426)
Stock-based compensation	53*	379*	263*	258	9*	256*	131*	208	249*	423*	357*	766
Depreciation and amortization	484	481	300*	449	399	398	400*	358	357	341	300*	314
Net cash from operating activities	589*	(919)*	(1,816)*	311	(283)*	490*	6,868*	600	(1,735)*	(1,339)*	(1,998)*	(492)
Purchases of property and equipment	153*	126*	(111)*	0	94*	42*	253*	46	242*	37*	239*	55
Net cash from investing activities	(153)*	(126)*	111*	0	(94)*	(42)*	(253)*	(46)	(242)*	(14)*	(238)*	(55)
Share repurchases	32*	0*	0*	0	0*	0*	0*	—	—	—	—	—
Net cash from financing activities	208*	0*	(145)*	(37)	239*	0*	(32)*	(14)	168*	(36)*	(19)*	33
Net change in cash	644*	(1,045)*	(1,850)*	274	(138)*	448*	6,583*	540	(1,809)*	(1,389)*	(2,255)*	(514)

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palatin Technologies	7,492	301*	(2,690)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.